Over the past few years, multiple biomarker strategies have been proposed as predictors of ICI therapy response; amongst others, tumor-infiltrating lymphocyte density, microsatellite instability (MSI), immunohistochemistry-based PD-L1 expression, and tumor mutational burden (TMB) [25]. Here, CD274 is linked to neoplasm.